Guoyi Yan

763 total citations
39 papers, 608 citations indexed

About

Guoyi Yan is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Guoyi Yan has authored 39 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 11 papers in Organic Chemistry and 10 papers in Oncology. Recurrent topics in Guoyi Yan's work include HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (6 papers) and Synthesis and biological activity (5 papers). Guoyi Yan is often cited by papers focused on HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (6 papers) and Synthesis and biological activity (5 papers). Guoyi Yan collaborates with scholars based in China, United States and Argentina. Guoyi Yan's co-authors include Rui Li, Xueyan Hou, Meng Zhou, Chunlan Pu, Xuan Han, Feng Wu, Hao Luo, Suke Lan, Zhenyu Ding and Zhi Li and has published in prestigious journals such as Journal of Medicinal Chemistry, Tetrahedron and Molecules.

In The Last Decade

Guoyi Yan

36 papers receiving 597 citations

Peers

Guoyi Yan
Andrii Monastyrskyi United States
Hui-Yi Shiao Taiwan
Xin Zhai China
Danny Hsu United States
Marilia Barreca Italy
Cuiting Peng China
Eva Řezníčková Czechia
Carrow I. Wells United States
Jessica Iegre United Kingdom
Andrii Monastyrskyi United States
Guoyi Yan
Citations per year, relative to Guoyi Yan Guoyi Yan (= 1×) peers Andrii Monastyrskyi

Countries citing papers authored by Guoyi Yan

Since Specialization
Citations

This map shows the geographic impact of Guoyi Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guoyi Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guoyi Yan more than expected).

Fields of papers citing papers by Guoyi Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guoyi Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guoyi Yan. The network helps show where Guoyi Yan may publish in the future.

Co-authorship network of co-authors of Guoyi Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Guoyi Yan. A scholar is included among the top collaborators of Guoyi Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guoyi Yan. Guoyi Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
Liu, Jianyu, et al.. (2024). Recent advances in dual PROTACs degrader strategies for disease treatment. European Journal of Medicinal Chemistry. 279. 116901–116901. 8 indexed citations
6.
Tao, Lianyuan, et al.. (2022). LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma. Laboratory Investigation. 102(5). 494–504. 36 indexed citations
7.
Pu, Chunlan, Yu Tong, Yuanyuan Liu, et al.. (2022). Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer. European Journal of Medicinal Chemistry. 236. 114321–114321. 34 indexed citations
8.
Li, Dongxiao, et al.. (2021). Identification of Critical Pathways and Potential Key Genes in Poorly Differentiated Pancreatic Adenocarcinoma. OncoTargets and Therapy. Volume 14. 711–723. 8 indexed citations
9.
Liu, Ge, et al.. (2021). Identification of critical pathways and potential therapeutic targets in poorly differentiated duodenal papilla adenocarcinoma. Cancer Cell International. 21(1). 9–9. 2 indexed citations
10.
Zhong, Xin-Xin, Rong‐Hua Luo, Guoyi Yan, et al.. (2021). Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis. European Journal of Medicinal Chemistry. 224. 113680–113680. 3 indexed citations
11.
Yan, Guoyi, Xin-Xin Zhong, Chunlan Pu, et al.. (2021). Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. Journal of Medicinal Chemistry. 64(3). 1558–1569. 9 indexed citations
12.
Ma, Xinyu, Guoyi Yan, Xin-Xin Zhong, et al.. (2021). Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold. European Journal of Medicinal Chemistry. 219. 113432–113432. 12 indexed citations
13.
Wang, Shan, Rong‐Hong Zhang, Hong Zhang, et al.. (2021). Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities. European Journal of Medicinal Chemistry. 222. 113573–113573. 28 indexed citations
14.
Yan, Guoyi, Xin-Xin Zhong, Yue Lin, et al.. (2021). Discovery of a PROTAC targeting ALK with in vivo activity. European Journal of Medicinal Chemistry. 212. 113150–113150. 41 indexed citations
15.
Yan, Guoyi, Dongxiao Li, Xin-Xin Zhong, et al.. (2020). Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics. 39(6). 1928–1939. 9 indexed citations
16.
Wang, Xueqin, Ping Lü, Lixia Zhu, et al.. (2019). Anti-CD133 Antibody-Targeted Therapeutic Immunomagnetic Albumin Microbeads Loaded with Vincristine-Assisted to Enhance Anti-Glioblastoma Treatment. Molecular Pharmaceutics. 16(11). 4582–4593. 14 indexed citations
17.
Zhang, Rong‐Hong, Shan Wang, Rong‐Hua Luo, et al.. (2019). Design, synthesis, and biological evaluation of 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif inhibitors. Bioorganic & Medicinal Chemistry Letters. 29(24). 126638–126638. 5 indexed citations
18.
Hu, Mingxing, et al.. (2019). Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. European Journal of Medicinal Chemistry. 182. 111608–111608. 18 indexed citations
19.
Yan, Guoyi, et al.. (2019). Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. European Journal of Medicinal Chemistry. 171. 265–281. 14 indexed citations
20.
Li, Zhi, Meng Zhou, Feng Wu, et al.. (2014). Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. Bioorganic & Medicinal Chemistry Letters. 24(3). 799–807. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrii Monastyrskyi Breakdown of academic impact, for papers by Hui-Yi Shiao Breakdown of academic impact, for papers by Xin Zhai Breakdown of academic impact, for papers by Danny Hsu Breakdown of academic impact, for papers by Marilia Barreca Breakdown of academic impact, for papers by Cuiting Peng Breakdown of academic impact, for papers by Eva Řezníčková Breakdown of academic impact, for papers by Carrow I. Wells Breakdown of academic impact, for papers by Jessica Iegre
Rankless by CCL
2026